![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GL Stahl, Z Terashita and AM Lefer
Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
The role of platelet activating factor (PAF) in acute myocardial ischemia (MI), produced by the ligation of the left main coronary artery, was studied in anesthetized rats. A significant loss of cardiac amino-nitrogen concentration and cathepsin D activity was observed 6 hr after permanent occlusion MI or 10 min of MI followed by 6 hr of reperfusion in rats. A novel, potent, PAF antagonist, CV-6209 (160 nmol/kg or 1.6 mumol/kg) injected after the ligation, significantly retarded the loss of amino-nitrogen and cathepsin D activity in a dose- related manner. In another group of rats, CV-6209 (1.6 mumol/kg) significantly blocked the hypotension induced by repetitive injections of PAF (570 pmol/kg) with an apparent half-life of approximately 180 min. In isolated rat hearts perfused with Krebs-Henseleit solution, PAF (25 nmol/l) significantly increased coronary perfusion pressure by 15 +/- 2 mmHg and induced an increase in cardiac permeability using fluorescein isothiocyanate bovine albumin as a marker. Furthermore, the increase in cardiac permeability induced in isolated perfused rat hearts undergoing 15 min global ischemia followed by reperfusion was significantly attenuated by CV-6209 (250 nmol/l). These data indicate that PAF is an important mediator of ischemic damage in rat MI. Moreover, the extension of ischemic damage may be enhanced by the increase in cardiac permeability induced by PAF.
This article has been cited by other articles:
|
|
 |
|
  V. Stangl, G. Baumann, K. Stangl, and S. B Felix Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion Cardiovasc Res, January 1, 2002; 53(1): 12 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Collard, A. Vakeva, M. A. Morrissey, A. Agah, S. A. Rollins, W. R. Reenstra, J. A. Buras, S. Meri, and G. L. Stahl Complement Activation after Oxidative Stress : Role of the Lectin Complement Pathway Am. J. Pathol., May 1, 2000; 156(5): 1549 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Vakeva, A. Agah, S. A. Rollins, L. A. Matis, L. Li, and G. L. Stahl Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion : Role of the Terminal Complement Components and Inhibition by Anti-C5 Therapy Circulation, June 9, 1998; 97(22): 2259 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Murohara, J. R. Horowitz, M. Silver, Y. Tsurumi, D. Chen, A. Sullivan, and J. M. Isner Vascular Endothelial Growth Factor/Vascular Permeability Factor Enhances Vascular Permeability Via Nitric Oxide and Prostacyclin Circulation, January 13, 1998; 97(1): 99 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Riera, J. Torras, I. Herrero, J. Valles, M. Paubert-Braquet, J. M. Cruzado, J. Alsina, and J. M. Grinyo Neutrophils Accentuate Renal Cold Ischemia-Reperfusion Injury. Dose-Dependent Protective Effect of a Platelet-Activating Factor Receptor Antagonist J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 786 - 794. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Gumina, J. E. Schultz, Z. Yao, D. Kenny, D. C. Warltier, P. J. Newman, and G. J. Gross Antibody to Platelet/Endothelial Cell Adhesion Molecule-1 Reduces Myocardial Infarct Size in a Rat Model of Ischemia-Reperfusion Injury Circulation, December 15, 1996; 94(12): 3327 - 3333. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Sawa, J. Schaper, M. Roth, K. Nagasawa, G. Ballagi, N. Bleese, and W. Schaper Platelet-activating factor plays an important role in reperfusion injury in myocardiumEfficacy of platelet-activating factor receptor antagonist (CV-3988) as compared with leukocyte-depleted reperfusion J. Thorac. Cardiovasc. Surg., November 1, 1994; 108(5): 953 - 959. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
